KALA BIO, Inc. (KALA) stock
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.43−0.40 (-10.44%)
Close on Nov 17, 2026Market cap $66.34MP/E –Yield –
Kala Bio total assets
Total assets on the balance sheet at the end of each period.
Kala Bio's total assets was $10.58M at Jun 30, 2026. For fiscal 2025 it was $9.49M, down 82.9% from the year before. The highest annual figure on record is $221.61M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.49M | -82.9% |
| FY2024 | Dec 31, 2024 | $55.48M | -0.8% |
| FY2023 | Dec 31, 2023 | $55.95M | -35.6% |
| FY2022 | Dec 31, 2022 | $86.82M | -37.7% |
| FY2021 | Dec 31, 2021 | $139.43M | -37.1% |
| FY2020 | Dec 31, 2020 | $221.61M | +43.6% |
| FY2019 | Dec 31, 2019 | $154.32M | -30.2% |
| FY2018 | Dec 31, 2018 | $220.97M | +89.6% |
| FY2017 | Dec 31, 2017 | $116.55M | +151.6% |
| FY2016 | Dec 31, 2016 | $46.33M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.58M | -70.6% |
| Q1 FY2026 | Mar 31, 2026 | $12.32M | -74.5% |
| Q4 FY2025 | Dec 31, 2025 | $9.49M | -82.9% |
| Q3 FY2025 | Sep 30, 2025 | $25.02M | -53.7% |
| Q2 FY2025 | Jun 30, 2025 | $36.05M | -41.5% |
| Q1 FY2025 | Mar 31, 2025 | $48.25M | -9.0% |
| Q4 FY2024 | Dec 31, 2024 | $55.48M | -0.8% |
| Q3 FY2024 | Sep 30, 2024 | $54.08M | -11.5% |
| Q2 FY2024 | Jun 30, 2024 | $61.61M | -7.4% |
| Q1 FY2024 | Mar 31, 2024 | $53.03M | -26.6% |
| Q4 FY2023 | Dec 31, 2023 | $55.95M | -35.6% |
| Q3 FY2023 | Sep 30, 2023 | $61.12M | -28.7% |
| Q2 FY2023 | Jun 30, 2023 | $66.50M | -21.7% |
| Q1 FY2023 | Mar 31, 2023 | $72.23M | -35.3% |
| Q4 FY2022 | Dec 31, 2022 | $86.82M | -37.7% |
| Q3 FY2022 | Sep 30, 2022 | $85.70M | -55.8% |
| Q2 FY2022 | Jun 30, 2022 | $84.98M | -60.6% |
| Q1 FY2022 | Mar 31, 2022 | $111.57M | -51.5% |
| Q4 FY2021 | Dec 31, 2021 | $139.43M | -37.1% |
| Q3 FY2021 | Sep 30, 2021 | $193.81M | -13.9% |
| Q2 FY2021 | Jun 30, 2021 | $215.46M | -12.2% |
| Q1 FY2021 | Mar 31, 2021 | $229.83M | -11.1% |
| Q4 FY2020 | Dec 31, 2020 | $221.61M | +43.6% |
| Q3 FY2020 | Sep 30, 2020 | $225.10M | +39.8% |
| Q2 FY2020 | Jun 30, 2020 | $245.51M | +37.3% |
| Q1 FY2020 | Mar 31, 2020 | $258.53M | +31.2% |
| Q4 FY2019 | Dec 31, 2019 | $154.32M | -30.2% |
| Q3 FY2019 | Sep 30, 2019 | $161.01M | +91.5% |
| Q2 FY2019 | Jun 30, 2019 | $178.82M | +87.1% |
| Q1 FY2019 | Mar 31, 2019 | $197.02M | +87.7% |
| Q4 FY2018 | Dec 31, 2018 | $220.97M | +89.6% |
| Q3 FY2018 | Sep 30, 2018 | $84.08M | -32.0% |
| Q2 FY2018 | Jun 30, 2018 | $95.59M | +234.3% |
| Q1 FY2018 | Mar 31, 2018 | $104.99M | +126.6% |
| Q4 FY2017 | Dec 31, 2017 | $116.55M | – |
| Q3 FY2017 | Sep 30, 2017 | $123.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $28.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $46.33M | – |
See a number that looks wrong?